Related Experiment Video
Updated: Sep 12, 2025

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Enhancing India's Health Security Efforts Against Mycobacterium Tuberculosis : Gaps and Opportunities
Abhijit Poddar1, Sourik Mukherjee1, S R Rao1
1Abhijit Poddar, PhD, is Chief, Centre for Bio-Policy Research (CBPR), Mahatma Gandhi Medical Advanced Research Institute (MGMARI), Sri Balaji Vidyapeeth (Deemed-to-be-University), Pondicherry, India, and co-founder of Genentech Regulatory Solutions LLP, Hyderabad, India. Sourik Mukherjee, MSc, is a Research Scholar, MGMARI, Sri Balaji Vidyapeeth (Deemed-to-be-University), Pondicherry, India. S. R. Rao, PhD, is Founder and Director, Genentech Regulatory Solutions LLP, Hyderabad, India, and Former Senior Advisor, Department of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi, India.
Abstract:
India bears a quarter of the world's tuberculosis (TB) burden. In 2018, the country set an ambitious goal to eliminate TB by 2025-5 years ahead of the global target. While India has launched several large-scale public health initiatives, including Pradhan Mantri TB Mukt Bharat Abhiyan and Ni-kshay Poshan Yojana, several challenges persist that threaten progress toward elimination. These include data transparency issues, overburdened healthcare systems, and an unrealistic timeline for achieving elimination. In this article, we highlight underaddressed health security challenges-including multidrug-resistant TB, weak biosafety infrastructure, relapse without posttreatment monitoring, environmental contributors like air pollution, and a lack of targeted strategies for tribal populations and undocumented immigrants-and call for a revised approach to TB elimination aligned with the global 2030 goal, emphasizing evidence-based policy, improved surveillance, workforce support, multisectoral coordination, and environmental and technological interventions.
More Related Videos
10:04Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
10:29A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...